Results for 'Pharmacy'
FollowBrowse oncology articles matching Pharmacy — expert analysis, clinical perspectives, and industry updates from across drug development and care delivery. Use the tabs above for podcasts, press releases, partners, and people for the same search.
Tom Caravela
Job Search Checklist for Aspiring Medical Science Liaisons
Medical Science Liaison, MSL role, MSL career tips, Pharmaceutical industry jobs, Break into MSL career
Tips to Help Break into Your First MSL Role The Medical Science Liaison (MSL) role, has become one of the most sought-after career paths in the Pharmaceutical and Biotech industry. What does it take to land a role as a Medical Science Liaison? As an MSL Recruiter, this is a question that I am…
May 17th • 2 mins read
Bridget Rasmusson
Positioning Yourself to Become an MSL in 2022
MSL role, clinical background, academic background, research background, industry, MSL Society, conference, scientific expert, therapeutic expertise, pharma companies
After attending the MSL Society’s 9th annual conference in Vegas Last week, I have taken some time to reflect on inquiries our team received about how to effectively step into the MSL role from a clinical, academic, or research background. Industry is a tough nut to crack, but it is absolutely…
Dec 21st • 10 mins read
YuQian Liu, PharmD
Uptake of Oncology Biosimilars: Managed Care Strategies to Improve Value-Based Care Systems
biosimilars in oncology, cost-effective cancer care, healthcare education, bioequivalence studies, biosimilar adoption, cancer treatment protocols
Biosimilars offer a cost-effective alternative in oncology, expanding access to cancer care, but their utilization is inconsistent due to varying perceptions and knowledge among stakeholders. Increasing the adoption of biosimilars requires improved education and understanding among healthcare pro…
Jul 7th • 25 mins read
Carina Dolan, PharmD, BCOP
Opportunities and challenges in biosimilar uptake in oncology
Trastuzumab, Rituximab, biosimiliar agents, emerging agents, cetuximab, bevacizumab, clinical trials, biosimiliars
The U.S. has 10 approved biosimilars, including 3 for oncology, with many more in development, potentially increasing access to expensive biologics. Acceptance by healthcare providers and patients requires extensive education, resolving concerns about immunogenicity, and ensuring interchangeability.…
Jun 26th • 7 mins read